These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2065329)

  • 1. Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways.
    Hudson MA; Brown EJ; Ritchey JK; Ratliff TL
    Cancer Res; 1991 Jul; 51(14):3726-32. PubMed ID: 2065329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
    Ratliff TL; Palmer JO; McGarr JA; Brown EJ
    Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.
    Kavoussi LR; Brown EJ; Ritchey JK; Ratliff TL
    J Clin Invest; 1990 Jan; 85(1):62-7. PubMed ID: 2404029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Enhancement of bacillus Calmette-Guerin attachment to the bladder wall: experimental study].
    Shen Z; Ding G; Chen Z
    Zhonghua Wai Ke Za Zhi; 2001 Dec; 39(12):951-3. PubMed ID: 16201181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria.
    Hudson MA; Ritchey JK; Catalona WJ; Brown EJ; Ratliff TL
    Cancer Res; 1990 Jul; 50(13):3843-7. PubMed ID: 2191767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits.
    Shen ZJ; Wang Y; Ding GQ; Pan CW; Zheng RM
    World J Urol; 2007 Oct; 25(5):525-9. PubMed ID: 17665201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer.
    Ratliff TL; Kavoussi LR; Catalona WJ
    J Urol; 1988 Feb; 139(2):410-4. PubMed ID: 3276931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Guerin for bladder urothelial cancer.
    Boorjian SA; Berglund RK; Maschino AC; Savage CJ; Herr HW
    J Urol; 2009 Oct; 182(4):1306-12. PubMed ID: 19683284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
    J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
    Zlotta A; Drowart A; van Vooren JP; Simon J; Schulman CC; Huygen K
    Acta Urol Belg; 1994 Sep; 62(3):63-8. PubMed ID: 7976857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
    Shapiro A; Ratliff TL; Oakley DM; Catalona WJ
    Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity.
    Zhao W; Schorey JS; Bong-Mastek M; Ritchey J; Brown EJ; Ratliff TL
    Int J Cancer; 2000 Apr; 86(1):83-8. PubMed ID: 10728599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacillus Calmette-Guérin induces the expression of peroxisome proliferator-activated receptor gamma in bladder cancer cells.
    Lodillinsky C; Umerez MS; Jasnis MA; Casabé A; Sandes E; Eiján AM
    Int J Mol Med; 2006 Feb; 17(2):269-73. PubMed ID: 16391825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycobacterial adherence and BCG treatment of superficial bladder cancer.
    Schamhart DH; de Boer EC; Bevers RF; Kurth KH; Steerenberg PA
    Prog Clin Biol Res; 1992; 378():75-80. PubMed ID: 1284504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Attachment of bacillus Calmette-Guerin to bladder cancer cells and the expression of interleukin-6 biological activity].
    Zhong H; Gu F; Yu L
    Zhonghua Wai Ke Za Zhi; 1995 Feb; 33(2):119-22. PubMed ID: 7656701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guérin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group.
    Witjes JA; vd Meijden AP; Doesburg W; Debruyne FM
    Eur Urol; 1993; 23(3):366-70. PubMed ID: 8508889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
    Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
    J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells.
    Kuroda K; Brown EJ; Telle WB; Russell DG; Ratliff TL
    J Clin Invest; 1993 Jan; 91(1):69-76. PubMed ID: 8423234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
    Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
    J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.